# EDGAR Filing Document

**Accession Number:** 0001799448
**File Stem:** 0001610717-26-000055
**Filing Date:** 2026-2
**Character Count:** 12659
**Document Hash:** 2234596e1cb360b2cefce7a8b6f0c1a6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001610717-26-000055.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0001610717-26-000055

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260129

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Aneja Nikhil
- **CENTRAL INDEX KEY:** 0002112438

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39617
- **FILM NUMBER:** 26655865

**MAIL ADDRESS:**
- **STREET 1:** C/O ALIGOS THERAPEUTICS, INC.
- **STREET 2:** ONE CORPORATE DRIVE, 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aligos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001799448
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE CORPORATE DR., 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (800) 466-6059

**MAIL ADDRESS:**
- **STREET 1:** ONE CORPORATE DR., 2ND FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

## Ex-24

```

                               POWER OF ATTORNEY
          With  respect  to holdings of and transactions in securities issued by
Aligos  Therapeutics,  Inc.,  a  Delaware  corporation  (the  "Company"),  the
undersigned  hereby  constitutes and appoints individuals of the Company holding
the  titles  named on Schedule A attached hereto and as may be amended from time
to  time,  or  any  of  them signing singly, with full power of substitution and
resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

      1.  prepare,  execute  in  the  undersigned's  name  and  on  the
      undersigned's  behalf,  and  submit  to  the  United States Securities and
      Exchange  Commission  (the "SEC") a Form ID, including amendments thereto,
      and  any  other  documents  necessary  or  appropriate  to  obtain  and/or
      regenerate  codes  and  passwords  enabling  the  undersigned  to  make
      electronic  filings  with  the SEC of reports required by Section 16(a) of
      the  Securities  Exchange  Act  of  1934,  as  amended,  or  any  rule  or
      regulation of the SEC;

      2.  execute  for  and  on  behalf of the undersigned, in the undersigned's
      capacity  as  an officer and/or director of the Company, (a) Schedules 13D
      and  13G  in  accordance with Section 13 of the Securities Exchange Act of
      1934,  as  amended  (the  "Exchange  Act"),  and the rules thereunder, (b)
      Forms  3,  4,  and  5  (including  amendments  thereto) in accordance with
      Section  16  of  the  Exchange  Act,  (c)  Notices  of  Proposed  Sale  of
      Securities  Pursuant  to  Rule  144  ("Form  144"), in accordance with the
      requirements  of  Rule  144  under  the Securities Act of 1933, as amended
      (the  "Securities Act"), and (d) a Form ID, Uniform Application for Access
      Codes to File on EDGAR;

      3.  do  and  perform  any  and  all  acts  for  and  on  behalf  of  the
      undersigned  which  may  be necessary or desirable to complete and execute
      any  such Schedule 13D, Schedule 13G, Forms 3, 4, 5, or 144 or Form ID, or
      any  amendment  thereto,  and timely file such forms (including amendments
      thereto)  and  application  with the SEC and any stock exchange or similar
      authority; and

      4.  take  any  other  action  of  any  type  whatsoever in connection with
      the  foregoing  which,  in the opinion of such attorney-in-fact, may be of
      benefit  to,  in  the  best  interest  of,  or  legally  required  by, the
      undersigned,  it  being  understood  that  the  documents executed by such
      attorney-in-fact  on  behalf  of the undersigned pursuant to this Power of
      Attorney  shall  be  in  such  form  and  shall  contain  such  terms  and
      conditions  as  such  attorney-in-fact  may  approve  in  such
      attorney-in-fact's discretion.

     The  undersigned hereby grants to each such attorney-in-fact full power and
     authority  to  do  and  perform  any  and  every  act  and thing whatsoever
     requisite,  necessary,  or  proper to be done in the exercise of any of the
     rights  and  powers herein granted, as fully to all intents and purposes as
     the  undersigned  might  or could do if personally present, with full power
     of  substitution  and  resubstitution  or  revocation, hereby ratifying and
     confirming  all  that  such  attorney-in-fact,  or  such  attorneys-in-fact
     substitute  or substitutes, shall lawfully do or cause to be done by virtue
     of this Power of Attorney and the rights and powers herein granted.

     The  undersigned  acknowledges  that  the  foregoing  attorneys-in-fact, in
serving  in  such  capacity at the request of the undersigned, are not assuming,
nor  is  the  Company  assuming,  any  of  the undersigned's responsibilities to
comply  with  Section  13  and  16  of  the  Exchange  Act or Rule 144 under the
Securities Act.

     The  undersigned  agrees  that  each  such attorney-in-fact herein may rely
entirely  on  information  furnished  orally or in writing by the undersigned to
such  attorney-in-fact.  The  undersigned  also  agrees  to  indemnify  and hold
harmless  the Company and each such attorney-in-fact against any losses, claims,
damages  or  liabilities (or actions in these respects) that arise out of or are
based  upon  any  untrue  statements  or  omission  of  necessary  facts  in the
information  provided  by  the undersigned to such attorney-in fact for purposes
of  executing,  acknowledging,  delivering  or  filing  Forms  3,  4,  5, or 144
(including  amendments  thereto)  or Form ID and agrees to reimburse the Company
and  such  attorney-in-fact  for any legal or other expenses reasonably incurred
in  connection  with  investigating  or  defending against any such loss, claim,
damage, liability, or action.

     This  Power  of  Attorney  supersedes  any  power  of  attorney  previously
executed  by  the  undersigned  regarding  the  purposes  outlined  in the first
paragraph  hereof  ("Prior  Powers  of  Attorney"),  and  the  authority  of the
attorneys-in-fact named in any Prior Powers of Attorney is hereby revoked.

     This  Power  of  Attorney  shall  remain in full force and effect until the
undersigned  is  no  longer required to file Schedule 13D or 13G and Forms 3, 4,
5,  or  144  with  respect  to the undersigned's holdings of and transactions in
securities  issued by the Company, unless earlier (a) revoked by the undersigned
in  a  signed  writing  delivered  to  the  foregoing  attorneys-in-fact  or (b)
superseded  by  a  new  power of attorney regarding the purposes outlined in the
first paragraph hereof dated as of a later date.

IN  WITNESS  WHEREOF,  the  undersigned  has  caused  this  Power of Attorney to
be executed as of this 5th day of February, 2026.

                                /s/ Nikhil Aneja

                                   Schedule A

Individuals of Aligos Therapeutics, Inc. Appointed as Attorney-in-Fact with
                 Full Power of Substitution and Resubstitution

Chief Executive Officer, who is currently Lawrence Blatt, Ph.D.
Chief Financial Officer, who is currently Lesley Ann Calhoun

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Aneja Nikhil<br><sub>(Last) (First) (Middle)</sub><br>C/O ALIGOS THERAPEUTICS, INC.<br>1 CORPORATE DRIVE, 2ND FLOOR<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Aligos Therapeutics, Inc. [ ALGS ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-01-29 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Principal Accounting Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2034-02-13 | Common Stock | 3800 | $16 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2034-09-04 | Common Stock | 2640 | $11.74 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2035-02-28 | Common Stock | 7155 | $16.87 | D |  |
| Stock Option (Right to Buy) | <sup>(4)</sup> | 2035-07-16 | Common Stock | 3600 | $8.68 | D |  |

---

### Footnotes:

(1) 25% of the total number of shares vest in one year and 1/36th of the remaining total number of shares vest in thirty-six (36) successive and equal monthly installments measured one year following February 13, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

(2) 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

(3) 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

(4) 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Lesley Ann Calhoun, as attorney-in fact for Nikhil Aneja  
**Date:** 2026-02-19

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**